Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabenazine SCHEMBL12394431 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29383441 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL13401094 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL62026 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29609598 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971241 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992566 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971276 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL20049732 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29380971 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322308-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-11026931-B2 | Methods for the administration of certain VMAT2 inhibitors | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10966922-B2 | Pharmaceutical formulations | AUSPEX PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200360354-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20190328661-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190133935-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10166183-B2 | Pharmaceutical formulations | AUSPEX PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3102190-A2 | NOVEL PHARMACEUTICAL FORMULATIONS | Auspex Pharmaceuticals, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160346200-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS LLC | 2016-12-01 | — | — | US | disclosed |
| WO-2015120110-A2 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026931-B2 | Methods for the administration of certain VMAT2 inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC18A2 1/4885KDM4E 3191/4885ABCB11 245/4885 |
| US-20190133935-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 57/4885KDM4E 4255/4885ABCB11 22/4885 |
| US-20210322308-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 57/4885KDM4E 4255/4885ABCB11 22/4885 |
| US-20200360354-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC18A2 1/4885KDM4E 3191/4885ABCB11 245/4885 |
| US-20190328661-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 57/4885KDM4E 4255/4885ABCB11 22/4885 |
| US-10966922-B2 | Pharmaceutical formulations | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 71/4885KDM4E 4290/4885ABCB11 6/4885 |
| US-20160346200-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | SI, CFTR, SUCNR1 | SLC18A2 100/4885KDM4E 3211/4885ABCB11 12/4885 |
| US-10166183-B2 | Pharmaceutical formulations | SI, CFTR, FABP6 | SLC18A2 248/4885KDM4E 2404/4885ABCB11 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.